SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Cited by papers we hold 13

• SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 · 2022
  No notice
• Predicting the mutational drivers of future SARS-CoV-2 variants of concern · 2022
  No notice
• SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns · 2021
  No notice
• SARS-CoV-2: from its discovery to genome structure, transcription, and replication · 2021
  No notice
• Natural selection in the evolution of SARS-CoV-2 in bats created a generalist virus and highly capable human pathogen · 2021
  No notice
• SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes · 2021
  No notice
• Type I and III interferon responses in SARS-CoV-2 infection · 2021
  No notice
• Innate immune sensing of coronavirus and viral evasion strategies · 2021
  No notice
• SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon · 2021
  Corrected
• Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic · 2021
  No notice
• Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be · 2020
  No notice
• Interplay between SARS-CoV-2 and the type I interferon response · 2020
  No notice
• ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.